Iovance Biotherapeutics, Inc. IOVA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
48/100
Developing

Ranked against 712 peers in Biotechnology

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable … Full IOVA analysis →

Key strengths

  • Operating Expense Control OpEx growth is controlled (score 0.68), demonstrating operating leverage.
  • Operating Leverage in Effect Operating leverage is evident (score 0.96), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 22.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • Elevated Debt Risk Debt serviceability is weak (score 0.29), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
19
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where IOVA ranks in Biotechnology

Iovance Biotherapeutics, Inc. ranks #264 of 713 scored companies in Biotechnology by moat score — the top 37%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
260 Context Therapeutics Inc. CNTX 48/100 Developing
261 Tyra Biosciences, Inc. TYRA 48/100 Developing
262 Rapport Therapeutics, Inc. RAPP 48/100 Developing
263 Ginkgo Bioworks Holdings, Inc. DNA 48/100 Developing
264 Iovance Biotherapeutics, Inc. IOVA 48/100 Developing
265 MBX Biosciences, Inc. MBX 48/100 Developing
266 Disc Medicine, Inc. IRON 48/100 Developing
267 Monopar Therapeutics Inc. MNPR 48/100 Developing
268 Intellia Therapeutics, Inc. NTLA 48/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How IOVA scores on the Corporate Default defenses

Pricing Power

Score 19 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 73 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 68 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 44 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 40 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 66 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding IOVA's moat

What is Iovance Biotherapeutics, Inc.'s moat score?

Iovance Biotherapeutics, Inc. (IOVA) scores 48 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #264 of 713 scored companies in Biotechnology, the top 37%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (73/100) and its weakest is Pricing Power (19/100).

How does Iovance Biotherapeutics, Inc. compare with other Biotechnology companies?

Iovance Biotherapeutics, Inc. ranks #264 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Ginkgo Bioworks Holdings, Inc. (DNA) at 48 just above it and MBX Biosciences, Inc. (MBX) at 48 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Iovance Biotherapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Iovance Biotherapeutics, Inc.?

The Corporate Default template measures 6 defenses, and IOVA scores: Pricing Power (19), Cost Advantage (73), Customer Stickiness (68), Capital Efficiency (44), Resilience (40), Scale & Market Position (66). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000